<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463161</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-1539</org_study_id>
    <nct_id>NCT03463161</nct_id>
  </id_info>
  <brief_title>Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy</brief_title>
  <acronym>ORKA</acronym>
  <official_title>A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine response rate of the combination of pembrolizumab plus epacadostat in
      patients with head and neck cancers that have received prior immunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to one of 2 study groups based on response to prior therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Rate of clinical disease response (tumor shrinkage) as seen on imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients that have not had disease worsening across both study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients surviving across both study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>6 months</time_frame>
    <description>Summary of side effects by type and severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.
Participants will receive Pembrolizumab and Epacadostat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.
Participants will receive Pembrolizumab and Epacadostat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.</description>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK3476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>Epacadostat (100mg) taken by mouth twice a day.</description>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <other_name>INCB024360</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Squamous cell carcinoma of the head and neck (which cannot be surgically removed and
             not amenable to curative intent therapy)

          -  Meet criteria for either the Acquired Resistance OR the Suboptimal Benefit Group *
             Acquired Resistance defined as (i and ii must both be met): i. Prior benefit from
             anti-PD-1/PD-L1 therapy defined as a) prior response, and/or b) ≥5 months of stable
             disease (SD). Intervening therapies are allowed.

        ii. Progressive Disease (PD) on recent scans

        * Suboptimal Benefit is defined as (i and ii must both be met): i. Prolonged stable disease
        ≥5 months OR Suboptimal response (&gt;10% &amp; &lt;50% shrinkage per RECIST at any evaluation
        timepoint) ii. Ongoing stable disease on recent scans iii. Last treatment with an
        anti-PD-1/PD-L1 agent within 6 weeks prior to starting protocol treatment

          -  Availability of stored tumor tissue OR new tumor biopsy Archival tissue for PD-L1
             staining (alternatively a new biopsy (core) at baseline can be used). A minimum of 10
             slides is required (unless approval from the PI is obtained)

          -  Measurable disease

          -  Known human papillomavirus (HPV) status

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Be willing and able to provide written informed consent for the trial.

          -  Aged 18 years or older

          -  Demonstrate reasonable organ function

          -  Women of childbearing potential should have a negative urine or serum pregnancy test

          -  Women of childbearing potential should be willing to use 2 methods of birth control or
             be surgically sterile, or abstain from heterosexual activity for the course of the
             study through 120 days after the last dose of study medication

          -  Males should agree to use an adequate method of birth control starting with the first
             dose of study therapy through 120 days after the last dose of study medication

        Exclusion Criteria:

          -  Currently participating and receiving treatment in a research study or has
             participated in a study of an investigational therapy and received study therapy or
             used an investigational device within 2 weeks of the first dose of treatment on this
             study

          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
             form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

          -  Known history of active TB (Bacillus Tuberculosis)

          -  Hypersensitivity to pembrolizumab, epacadostat or any of its excipients.

          -  Has received prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study
             Day 1, or targeted small molecule therapy within 2 weeks prior to study Day 1, or who
             has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier.

          -  Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse
             events due to a previous treatment/ administered agent (i.e., ≤ Grade 1 or return to
             baseline prior to treatment).

        Note: Participants with ≤ Grade 2 neuropathy, any grade hearing loss or tinnitus, or
        typical side effects from radiotherapy are an exception to this criterion and may qualify
        for the study.

        Note: If subject received major surgery, they must have recovered adequately from the
        toxicity and/or complications from the intervention prior to starting therapy.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer or any
             tumors that are not likely to influence live expectancy in the subsequent 3 years
             without active treatment (e.g. low grade prostate cancer in absence of therapy).

          -  Has known active (=growing) central nervous system (CNS) metastases and/or
             carcinomatous meningitis. Radiation or resected brain metastasis are acceptable if
             clinically stable.

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has known history of, or any evidence of active, non-infectious pneumonitis.

          -  Warfarin use, even if low dose warfarin is not acceptable. However, other
             anti-coagulants (e.g. aspirin, enoxaparin and heparin derivatives, thrombin
             inhibitors, etc) are acceptable.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an IDO inhibiting agent.

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

          -  Has received a live vaccine within 30 days of planned start of study therapy.

          -  Has received MAO-inhibitors (MAOI) or drug which has significant MAOI activity
             (meperidine, linezolid, methylene blue) within the 21 days before screening.

          -  History of Serotonin Syndrome after receiving serotonergic drugs.

          -  History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's
             opinion, is clinically meaningful. Screening QTc interval &gt; 470 milliseconds is
             excluded.

          -  Use of any UGT1A9 inhibitor from screening through follow-up period, including the
             following: diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid. See
             Section 5.11 for more details.

          -  History of organ transplant that requires use of immunosuppressives.

          -  Any condition that would jeopardize the safety of the subject or compliance with the
             Protocol.

          -  Clinically significant cardiac disease, including unstable angina, acute myocardial
             infarction within 6 months from Day 1 of study drug administration, New York Heart
             Association Class III or IV congestive heart failure, and arrhythmia requiring therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allison Dekker, RN</last_name>
    <phone>(773) 702-2068</phone>
    <email>adekker@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison E. Dekker</last_name>
      <phone>773-702-2068</phone>
      <email>adekker@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Tanguy Seiwert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

